Styliani Vakrou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Styliani Vakrou has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Frogoudaki
2nd Cardiology Department, Attikon University Hospital National and Kapodistrian University of Athens Athens Greece
2 shared publications - Achilleas Zacharoulis
Cardiology Department, Evaggelismos General Hospital, Athens, Greece
1 shared publication Aikaterini Naka
Cardiology Department, Ioannina University Hospital, Ioannina, Greece
1 shared publicationAlexandros Kasiakogias
1 shared publicationAlexios S. Antonopoulos
1(st) Cardiology Department, Hippokration Hospital, National and Kapodistrian University of Athens, Greece
1 shared publication- Alexios S. Antonopoulos
First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 115 27 Athens, Greece
1 shared publication
Latest Publications
- Open Access
- 4 October 2026
- Published by MDPI AG in Applied Sciences
- Vol. 16 (19) , 9837
Design, Development, Integration and Technical Validation of a Large-Scale Digital Health Platform for Remote Monitoring and Management of Patients with Advanced Heart Failure
Digital health solutions increasingly rely on interoperable software platforms that integrate heterogeneous data sources, support remote patient monitoring and deliver clinical decision support while complying with strict security, privacy and regulatory requirements. Numerous studies report the clinical outcomes or analytical capabilities of such systems. However, the engineering processes leading to their development are rarely described in a systematic manner. This paper presents the design, development, integration and technical validation of the RETENTION digital health platform for the remote monitoring and management of advanced heart failure patients. The platform was developed as a modular software ecosystem integrating mobile and web applications, medical devices, clinical and real-world data repositories, and artificial intelligence services through an HL7 FHIR-centred architecture. The complete engineering lifecycle, from requirements and architecture to software development, integration and validation, is described in this paper. Emphasis is placed on the adoption of interoperability standards, Security and Privacy by Design principles, data management mechanisms and deployment strategies that enable the integration of heterogeneous technologies into a unified platform. By documenting the complete development pathway, this work aims to serve as a guide for the design and implementation of large-scale digital health platforms that support remote patient monitoring and chronic disease management.
- 4 October 2026
- Published by MDPI AG in Applied Sciences
- Vol. 16 (19) , 9837
Open AccessDesign, Development, Integration and Technical Validation of a Large-Scale Digital Health Platform for Remote Monitoring and Management of Patients with Advanced Heart Failure
Digital health solutions increasingly rely on interoperable software platforms that integrate heterogeneous data sources, support remote patient monitoring and deliver clinical decision support while complying with strict security, privacy and regulatory requirements. Numerous studies report the clinical outcomes or analytical capabilities of such systems. However, the engineering processes leading to their development are rarely described in a systematic manner. This paper presents the design, development, integration and technical validation of the RETENTION digital health platform for the remote monitoring and management of advanced heart failure patients. The platform was developed as a modular software ecosystem integrating mobile and web applications, medical devices, clinical and real-world data repositories, and artificial intelligence services through an HL7 FHIR-centred architecture. The complete engineering lifecycle, from requirements and architecture to software development, integration and validation, is described in this paper. Emphasis is placed on the adoption of interoperability standards, Security and Privacy by Design principles, data management mechanisms and deployment strategies that enable the integration of heterogeneous technologies into a unified platform. By documenting the complete development pathway, this work aims to serve as a guide for the design and implementation of large-scale digital health platforms that support remote patient monitoring and chronic disease management.
- Open Access
- 10 March 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (3)
Integrating Genetic Counseling in Cardiology Clinics: From Guidelines to Practice
- 10 March 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (3)
Open AccessIntegrating Genetic Counseling in Cardiology Clinics: From Guidelines to Practice
- Open Access
- 15 July 2021
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 117 (1) , 157-159
Estratificação de Risco para Prevenção Primária de Morte Súbita Cardíaca em Cardiomiopatia Hipertrófica
Carta-resposta A morte súbita cardíaca (MSC) é considerada a complicação mais dramática da cardiomiopatia hipertrófica (CMH), com uma incidência anual estimada de 0,5–1%. Ao longo dos anos, ACC/AHA e ESC publicaram diretrizes de consenso que apresentam diferentes abordagens para a estratificação de risco de MSC com base em preditores clínicos independentes. Apesar da acurácia relativamente baixa desses marcadores, as estratégias atuais teriam razoável poder discriminatório para o reconhecimento de pacientes de alto risco. No entanto, a avaliação prognóstica é um [...] Carta-resposta A morte súbita cardíaca (MSC) é considerada a complicação mais dramática da cardiomiopatia hipertrófica (CMH), com uma incidência anual estimada de 0,5–1%. Ao longo dos anos, ACC/AHA e ESC publicaram diretrizes de consenso que apresentam diferentes abordagens para a estratificação de risco de MSC com base em preditores clínicos independentes. Apesar da acurácia relativamente baixa desses marcadores, as estratégias atuais teriam razoável poder discriminatório para o reconhecimento de pacientes de alto risco. No entanto, a avaliação prognóstica é um
- 15 July 2021
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 117 (1) , 157-159
Open AccessEstratificação de Risco para Prevenção Primária de Morte Súbita Cardíaca em Cardiomiopatia Hipertrófica
Carta-resposta A morte súbita cardíaca (MSC) é considerada a complicação mais dramática da cardiomiopatia hipertrófica (CMH), com uma incidência anual estimada de 0,5–1%. Ao longo dos anos, ACC/AHA e ESC publicaram diretrizes de consenso que apresentam diferentes abordagens para a estratificação de risco de MSC com base em preditores clínicos independentes. Apesar da acurácia relativamente baixa desses marcadores, as estratégias atuais teriam razoável poder discriminatório para o reconhecimento de pacientes de alto risco. No entanto, a avaliação prognóstica é um [...] Carta-resposta A morte súbita cardíaca (MSC) é considerada a complicação mais dramática da cardiomiopatia hipertrófica (CMH), com uma incidência anual estimada de 0,5–1%. Ao longo dos anos, ACC/AHA e ESC publicaram diretrizes de consenso que apresentam diferentes abordagens para a estratificação de risco de MSC com base em preditores clínicos independentes. Apesar da acurácia relativamente baixa desses marcadores, as estratégias atuais teriam razoável poder discriminatório para o reconhecimento de pacientes de alto risco. No entanto, a avaliação prognóstica é um
- 6 December 2020
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 121 (06) , 703-715
Cardiometabolic Syndrome: An Update on Available Mouse Models
Cardiometabolic syndrome (CMS), a disease entity characterized by abdominal obesity, insulin resistance (IR), hypertension, and hyperlipidemia, is a global epidemic with approximately 25% prevalence in adults globally. CMS is associated with increased risk for cardiovascular disease (CVD) and development of diabetes. Due to its multifactorial etiology, the development of several animal models to simulate CMS has contributed significantly to the elucidation of the disease pathophysiology and the design of therapies. In this review we aimed to present the most common mouse models used in the research of CMS. We found that CMS can be induced either by genetic manipulation, leading to dyslipidemia, lipodystrophy, obesity and IR, or obesity and hypertension, or by administration of specific diets and drugs. In the last decade, the ob/ob and db/db mice were the most common obesity and IR models, whereas Ldlr−/− and Apoe−/− were widely used to induce hyperlipidemia. These mice have been used either as a single transgenic or combined with a different background with or without diet treatment. High-fat diet with modifications is the preferred protocol, generally leading to increased body weight, hyperlipidemia, and IR. A plethora of genetically engineered mouse models, diets, drugs, or synthetic compounds that are available have advanced the understanding of CMS. However, each researcher should carefully select the most appropriate model and validate its consistency. It is important to consider the differences between strains of the same animal species, different animals, and most importantly differences to human when translating results. * These authors contributed equally to this work as senior authors. Received: 03 June 2020 Accepted: 24 October 2020 Publication Date: 06 December 2020 (online) © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 6 December 2020
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 121 (06) , 703-715
Cardiometabolic Syndrome: An Update on Available Mouse Models
Cardiometabolic syndrome (CMS), a disease entity characterized by abdominal obesity, insulin resistance (IR), hypertension, and hyperlipidemia, is a global epidemic with approximately 25% prevalence in adults globally. CMS is associated with increased risk for cardiovascular disease (CVD) and development of diabetes. Due to its multifactorial etiology, the development of several animal models to simulate CMS has contributed significantly to the elucidation of the disease pathophysiology and the design of therapies. In this review we aimed to present the most common mouse models used in the research of CMS. We found that CMS can be induced either by genetic manipulation, leading to dyslipidemia, lipodystrophy, obesity and IR, or obesity and hypertension, or by administration of specific diets and drugs. In the last decade, the ob/ob and db/db mice were the most common obesity and IR models, whereas Ldlr−/− and Apoe−/− were widely used to induce hyperlipidemia. These mice have been used either as a single transgenic or combined with a different background with or without diet treatment. High-fat diet with modifications is the preferred protocol, generally leading to increased body weight, hyperlipidemia, and IR. A plethora of genetically engineered mouse models, diets, drugs, or synthetic compounds that are available have advanced the understanding of CMS. However, each researcher should carefully select the most appropriate model and validate its consistency. It is important to consider the differences between strains of the same animal species, different animals, and most importantly differences to human when translating results. * These authors contributed equally to this work as senior authors. Received: 03 June 2020 Accepted: 24 October 2020 Publication Date: 06 December 2020 (online) © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 22 March 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (6)
Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models
Hypertrophic cardiomyopathy (HCM) stems from mutations in sarcomeric proteins that elicit distinct biophysical sequelae, which in turn may yield radically different intracellular signaling and molecular pathologic profiles. These signaling events remain largely unaddressed by clinical trials that have selected patients based on clinical HCM diagnosis, irrespective of genotype. In this study, we determined how two mouse models of HCM differ, with respect to cellular/mitochondrial function and molecular biosignatures, at an early stage of disease. We show that hearts from young R92W-TnT and R403Q-αMyHC mutation–bearing mice differ in their transcriptome, miRNome, intracellular redox environment, mitochondrial antioxidant defense mechanisms, and susceptibility to mitochondrial permeability transition pore opening. Pathway analysis of mRNA-sequencing data and microRNA profiles indicate that R92W-TnT mutants exhibit a biosignature consistent with activation of profibrotic TGF-β signaling. Our results suggest that the oxidative environment and mitochondrial impairment in young R92W-TnT mice promote activation of TGF-β signaling that foreshadows a pernicious phenotype in young individuals. Of the two mutations, R92W-TnT is more likely to benefit from anti–TGF-β signaling effects conferred by angiotensin receptor blockers and may be responsive to mitochondrial antioxidant strategies in the early stage of disease. Molecular and functional profiling may therefore serve as aids to guide precision therapy for HCM.
- 22 March 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (6)
Open AccessAllele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models
Hypertrophic cardiomyopathy (HCM) stems from mutations in sarcomeric proteins that elicit distinct biophysical sequelae, which in turn may yield radically different intracellular signaling and molecular pathologic profiles. These signaling events remain largely unaddressed by clinical trials that have selected patients based on clinical HCM diagnosis, irrespective of genotype. In this study, we determined how two mouse models of HCM differ, with respect to cellular/mitochondrial function and molecular biosignatures, at an early stage of disease. We show that hearts from young R92W-TnT and R403Q-αMyHC mutation–bearing mice differ in their transcriptome, miRNome, intracellular redox environment, mitochondrial antioxidant defense mechanisms, and susceptibility to mitochondrial permeability transition pore opening. Pathway analysis of mRNA-sequencing data and microRNA profiles indicate that R92W-TnT mutants exhibit a biosignature consistent with activation of profibrotic TGF-β signaling. Our results suggest that the oxidative environment and mitochondrial impairment in young R92W-TnT mice promote activation of TGF-β signaling that foreshadows a pernicious phenotype in young individuals. Of the two mutations, R92W-TnT is more likely to benefit from anti–TGF-β signaling effects conferred by angiotensin receptor blockers and may be responsive to mitochondrial antioxidant strategies in the early stage of disease. Molecular and functional profiling may therefore serve as aids to guide precision therapy for HCM.